Abstract: An ophthalmic composition can include dexamethasone phosphate, or a salt thereof, dexamethasone, but in an amount not greater than 1.0 wt % relative to the amount of dexamethasone phosphate, or a salt thereof, and water. The ophthalmic composition can have a pH of about 5 to about 8 and a tonicity of from about 100 mOsm/kg to about 760 mOsm/kg.

Abstract: A lipoic acid formulation can include water and an amount of a lipoic acid agent dissolved in the water. In some examples, a buffering agent can also be included in the formulation in an amount sufficient to dissolve the lipoic acid agent in the water. The lipoic acid formulation can generally have a pH of from about 6 to about 8.

Abstract: The present invention provides methods and devices for delivering an active agent into the eye of a subject. In one aspect, for example, the present invention provides an ocular drug delivery device including a housing configured to couple to the eye of the subject and a corneal seal coupled to the housing and positioned in the housing to encircle the cornea during use to form a corneal region, where the housing extends outward from the corneal seal to form a scleral region, and where the scleral region being positioned over the eye's sclera during use. The device further includes an active agent reservoir coupled to the housing and positioned to release active agent into the scleral region and a pressure regulator coupled to the housing that is operable to introduce negative pressure between the housing and the eye. Thus the corneal seal is operable to fluidically isolate the corneal region from the scleral region in response to the negative pressure.

Abstract: A non-invasive ocular drug delivery device can include a housing adapted to couple to an eye of a subject. An active agent matrix can be coupled to the housing. The active agent matrix can include an electrospun material having a combination of a density, a thickness, and an ocular surface area configured to hold and retain an active agent prior to application of the device to the eye, and deliver an effective dose of an active agent within 30 minutes of application of the device to the eye.

Abstract: The present invention provides methods and devices for delivering an active agent into the eye of a subject. In one aspect, for example, the present invention provides an ocular drug delivery device including a housing configured to couple to the eye of the subject and a corneal seal coupled to the housing and positioned in the housing to encircle the cornea during use to form a corneal region, where the housing extends outward from the corneal seal to form a scleral region, and where the scleral region being positioned over the eye's sclera during use. The device further includes an active agent reservoir coupled to the housing and positioned to release active agent into the scleral region and a pressure regulator coupled to the housing that is operable to introduce negative pressure between the housing and the eye. Thus the corneal seal is operable to fluidically isolate the corneal region from the scleral region in response to the negative pressure.

Abstract: An ophthalmic composition can include dexamethasone phosphate, or a salt thereof, dexamethasone, but in an amount not greater than 1.0 wt % relative to the amount of dexamethasone phosphate, or a salt thereof, and water. The ophthalmic composition can have a pH of about 5 to about 8 and a tonicity of from about 100 mOsm/kg to about 760 mOsm/kg.

Abstract: A non-invasive ocular drug delivery device can include a housing adapted to couple to an eye of a subject. An active agent matrix can be coupled to the housing. The active agent matrix can include an electro spun material having a combination of a density, a thickness, and an ocular surface area configured to hold and retain an active agent prior to application of the device to the eye, and deliver an effective dose of an active agent within 30 minutes of application of the device to the eye.

Abstract: A method of treating a subject with an ocular condition responsive to steroid therapy can include administering a threshold dose of a steroid to an eye of the subject in a therapeutically effective regimen that minimizes an intraocular pressure (IOP) increase above a baseline level.

Abstract: The present invention includes methods and devices for delivering an active agent into the eye of a subject. One such device may include an anode assembly having an anode housing and an anode configured to electrically couple to a power source, the anode assembly being configured to contact and remain against a surface of the eye. The device may also include a cathode assembly having a cathode housing and a cathode configured to electrically couple to the power source, the cathode assembly being configured to contact and remain against the surface of the eye. Additionally, the device may include at least one active agent reservoir functionally associated with at least one of the anode assembly and the cathode assembly.

Abstract: The present invention provides methods and devices for delivering an active agent into the eye of a subject. In one aspect, for example, the present invention provides an ocular drug delivery device including a housing configured to couple to the eye of the subject and a corneal seal coupled to the housing and positioned in the housing to encircle the cornea during use to form a corneal region, where the housing extends outward from the corneal seal to form a scleral region, and where the scleral region being positioned over the eye's sclera during use. The device further includes an active agent reservoir coupled to the housing and positioned to release active agent into the scleral region and a pressure regulator coupled to the housing that is operable to introduce negative pressure between the housing and the eye. Thus the corneal seal is operable to fluidically isolate the corneal region from the scleral region in response to the negative pressure.

Abstract: The present invention includes methods and devices for delivering an active agent into the eye of a subject. One such device may include an anode assembly having an anode housing and an anode configured to electrically couple to a power source, the anode assembly being configured to contact and remain against a surface of the eye. The device may also include a cathode assembly having a cathode housing and a cathode configured to electrically couple to the power source, the cathode assembly being configured to contact and remain against the surface of the eye. Additionally, the device may include at least one active agent reservoir functionally associated with at least one of the anode assembly and the cathode assembly.

Abstract: Methods and devices for delivering an active agent into the eye of a subject are provided. In one aspect, an ocular device for delivering an active agent through a cornea of an eye of a subject can include a housing configured to couple to the eye of the subject and a corneal seal coupled to the housing and positioned in the housing to encircle the cornea during use to form a corneal region. The device can also include an active agent reservoir coupled to the housing and positioned to release active agent into the corneal region, and a pressure regulator coupled to the housing and operable to introduce negative pressure between the housing and the eye. The corneal seal is operable to fluidically isolate the corneal region from the sclera in response to the negative pressure, thus minimizing contact of the active agent with the sclera.

Abstract: The present invention includes methods and devices for non-invasively delivering an active agent to the eye of a subject. In one aspect, for example, a device for delivering an active agent to an eye of a subject may include an ocular lens-shaped housing configured to contact a surface of the eye, and a reservoir coupled to the housing and configured to deliver an active agent to the eye, wherein the reservoir is located entirely within a 180 degree section of the housing. In another aspect, the reservoir is located entirely within a 150 degree section of the housing.

Abstract: The present invention provides methods and devices for delivering an active agent into the eye of a subject. In one aspect, for example, the present invention provides an ocular drug delivery device including a housing configured to couple to the eye of the subject and a corneal seal coupled to the housing and positioned in the housing to encircle the cornea during use to form a corneal region, where the housing extends outward from the corneal seal to form a scleral region, and where the scleral region being positioned over the eye's sclera during use. The device further includes an active agent reservoir coupled to the housing and positioned to release active agent into the scleral region and a pressure regulator coupled to the housing that is operable to introduce negative pressure between the housing and the eye. Thus the corneal seal is operable to fluidically isolate the corneal region from the scleral region in response to the negative pressure.

Abstract: The present invention includes methods and devices for providing sustained in-vivo release of an active agent to a subject. In some aspects, such release may be achieved by reacting an active agent in-vivo with a depot forming agent in order to form a sustained release active agent depot inside the subject. The depot can then release the active agent over a sustained period of time.

Abstract: The present invention includes methods and devices for non-invasively delivering an active agent to the eye of a subject. In one aspect, for example, a device for delivering an active agent to an eye of a subject may include an ocular lens-shaped housing configured to contact a surface of the eye, and a reservoir coupled to the housing and configured to deliver an active agent to the eye, wherein the reservoir is located entirely within a 180 degree section of the housing. In another aspect, the reservoir is located entirely within a 150 degree section of the housing.

Abstract: Methods and systems for preventing or treating various ocular conditions are disclosed and described. In one aspect, for example, a method for noninvasively delivering a water insoluble macrolide into an eye of a subject for treatment of an ocular condition is provided. Such a method may include administering non-invasively a water soluble form of the macrolide directly into an eye of a subject having or at risk for having the ocular condition, wherein the water soluble form is converted into the water insoluble macrolide in the eye in order to treat the ocular condition.

Abstract: The present invention provides methods and devices for the passive delivery of active agents into the eye of a subject. In one aspect, for example, a device for passively delivering an active agent into an eye of a subject may include a housing configured to conform to at least a portion of an eye surface, and a first reservoir component located within the housing and configured to be fluidically coupled to a first ocular surface, where the first reservoir contains an ionized active agent. The device may further include a second reservoir component located within the housing and configured to be fluidically coupled to a second ocular surface located adjacent to the first ocular surface, where the second reservoir component contains a depot forming agent having a charge that is opposite in polarity as compared to the ionized active agent.

Abstract: The present invention includes methods and devices for non-invasively delivering an active agent to the eye of a subject. In one aspect, for example, a device for delivering an active agent to an eye of a subject may include an ocular lens-shaped housing configured to contact a surface of the eye, and a reservoir coupled to the housing and configured to deliver an active agent to the eye, wherein the reservoir is located entirely within a 180 degree section of the housing. In another aspect, the reservoir is located entirely within a 150 degree section of the housing.

Abstract: The present invention includes techniques for delivering an active agent into the eye of a subject. Accordingly, in one aspect a method may include delivering invasively an active agent into a peripheral tissue of the eye to form a drug reservoir, and applying an electric current to the drug reservoir to thus drive at least a portion of the active agent at least partially through the choroid. Numerous configurations are contemplated for the positioning of the electric current relative to the drug reservoir. For example, in one aspect the electric current may be applied to the drug reservoir from a non-invasively positioned electrode. In another aspect, the electric current may be applied to the drug reservoir from an invasively positioned electrode. A variety of invasive positions are contemplated, including, for example, positioning the invasive electrode within the peripheral tissue.